Evidence map›Paper›PMID 30293439›Full record

ArticleThe Annals of pharmacotherapy2019

Rituximab Exhibits Altered Pharmacokinetics in Patients With Membranous Nephropathy.

Uma Fogueri, Wisit Cheungapasitporn, David Bourne, Fernando C Fervenza, Melanie S Joy

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Annals of pharmacotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Uma Fogueri1 Skaggs School of Pharmacy and Pharmaceutical sciences, University of Colorado, Aurora, CO, USA.
Wisit Cheungapasitporn2 Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
David Bourne1 Skaggs School of Pharmacy and Pharmaceutical sciences, University of Colorado, Aurora, CO, USA.
Fernando C Fervenza2 Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Melanie S Joy1 Skaggs School of Pharmacy and Pharmaceutical sciences, University of Colorado, Aurora, CO, USA.
University of Colorado Anschutz Medical Campus · USMayo Clinic · US

Funding

Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney DiseaseR01GM107122 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI JOY, MELANIE S, NOLIN, THOMAS DOUGLAS · 2014 to 2018
$2.3M
Drug Disposition and NephrotoxicityR01GM123330 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI ALEKSUNES, LAUREN M, JOY, MELANIE S · 2018 to 2021
$2.1M
NIGMS NIH HHS R01 GM107122NIGMS NIH HHS R01 GM123330
6 · The paper itself

Abstract

backgroundRituximab (RTX) is a chimeric monoclonal anti-CD20 antibody used off-label in the treatment of membranous nephropathy (MN). Unfortunately, limited information is available on the pharmacokinetics of therapeutic proteins such as RTX in patients with glomerular kidney diseases.

objectiveThe current study evaluated RTX pharmacokinetics in patients with MN (n = 20) who received 4 RTX weekly intravenous infusions (375 mg/m

methodsCompartmental pharmacokinetic analyses were conducted using Phoenix, and comparisons of these parameters were made between the MN patients and published data from 2 reference populations without kidney diseases (follicular lymphoma and autoimmune disorders).

resultsPatients with MN exhibited a shorter half-life, reduced volume of central compartment, decreased area under the serum concentration-time curve (exposure), and increased RTX clearance from the central compartment versus previous reports in the reference patient populations. CONCLUSIONS AND RELEVANCE: These results suggest that shorter half-life and lower exposures to RTX in patients with MN may necessitate higher doses and/or changes to dosing frequency to optimize the relationships between serum concentrations and therapeutic effects.

Indexed as

AdultAutoimmune DiseasesFemaleGlomerulonephritis, MembranousHalf-LifeHumansInfusions, IntravenousMaleMetabolic Clearance RateMiddle AgedOff-Label UseRituximabRituximabclearancemembranous nephropathymonoclonal antibodypharmacokineticsrituximab

Identifiers

PMID30293439
PMCPMC6629258
OpenAlexW2896878276

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.